N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss the latest interim results. Nigel talks us through the highlights of the first half, expands on a new refined strategy
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, has announced its unaudited interim results for the six months ended 30
N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss its Covid-19 proof of concept work utilising Nuvec® loaded with Coronavirus plasmid. Nigel provides us with a snapshot of the
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing, a novel delivery system for cancer treatments and vaccines, announces that it has appointed the API and Nanomedicines business unit of
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
